Inovio announces positive HPV vaccine PhIIb results; NanoBio's genital herpes candidate shows efficacy in animal model;

> Inovio Pharmaceuticals ($INO) reported positive Phase IIb studies of its VGX-3100, announcing that in women with high grade cervical neoplasia, the immunotherapy produced killer T cells that were able to clear lesions and the HPV virus itself. Release

> Ann Arbor, MI-based NanoBio announced that its adjuvanted genital herpes vaccine candidate showed efficacy in guinea pigs. Statement

> IDK Biologika opened its first U.S. vaccine manufacturing plant in Rockville, MD. Announcement

> Abivax named Dr. Jean-Marc Steens its chief medical officer. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.